Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 9,145 matching trials from the live ClinicalTrials.gov search.

Filters: Rochester, Minnesota Clear all

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF
Interventions: Greater Splanchnic Nerve Ablation, Sham Control; Device
Lead sponsor: Axon Therapies, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 24
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 17 more

Conditions: Endoscopic Retrograde Cholangiopancreatography
Interventions: Exalt Model D Single-Use Duodenoscope; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 6
States / cities: Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 3 more

Conditions: Cystic Fibrosis
Interventions: Lumacaftor, Ivacaftor, Lumacaftor Placebo, Ivacaftor Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 38
States / cities: Birmingham, Alabama • Anchorage, Alaska • La Jolla, California + 35 more

Conditions: Primary Mitochondrial Disease
Interventions: KL1333, Placebo; Drug
Lead sponsor: Pharming Technologies B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 20
States / cities: Orange, California • San Diego, California • San Francisco, California + 15 more

Conditions: Gastrointestinal Neoplasm
Interventions: Sutent; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 32
States / cities: Duarte, California • Pasadena, California • San Francisco, California + 24 more

Conditions: Bipolar Disorder
Interventions: Measurement based care; Other
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Rochester, Minnesota • Seattle, Washington

Conditions: Lipodystrophy, Familial Partial
Interventions: High fat mixed meal; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pemphigus
Interventions: Rilzabrutinib, Placebo; Drug
Lead sponsor: Principia Biopharma, a Sanofi Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 14
States / cities: Boca Raton, Florida • Coral Gables, Florida • Atlanta, Georgia + 9 more

Conditions: Smoking, Bipolar Disorder, Depression
Interventions: Varenicline; Drug
Lead sponsor: Mark Frye; Other
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: oxaliplatin; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 73
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more

Conditions: Crohn's Disease
Interventions: Risankizumab, Lutikizumab, Trosunilimab, ABBV-8736; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 64
States / cities: Dothan, Alabama • Mobile, Alabama • Coronado, California + 56 more

Conditions: Breast Cancer
Interventions: Palbociclib, Standard Adjuvant Endocrine Therapy; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 5,796 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 192
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 138 more

Conditions: Distal Pancreatectomy
Interventions: SEAMGUARD with bioabsorbable staple, TissueLink with radiofrequency ablation; Device · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Boston, Massachusetts • Rochester, Minnesota

Conditions: Amyloidosis
Interventions: 18-F Florbetapir PET/MR scan; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 100 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Myocardial Infarction
Interventions: i-STAT hs-TnI Cartridge Testing on i-STAT 1 and i-STAT Alinity; Diagnostic Test
Lead sponsor: Abbott Point of Care; Industry
Eligibility: 18 Years and older
Enrollment: 3,697 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 28
States / cities: Chandler, Arizona • San Francisco, California • Stanford, California + 25 more

Conditions: Cardiac Rhythm Disorder, Bradycardia
Interventions: Aveir VR Leadless Pacemaker System; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 1,276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 38
States / cities: Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 32 more

Conditions: Malignant Hepatobiliary Neoplasm
Interventions: Acceptance and Commitment Therapy, Questionnaire Administration, Telemedicine; Behavioral · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Arthralgia, Breast Cancer, Hot Flashes, Musculoskeletal Complications, Sexual Dysfunction
Interventions: testosterone, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 528
States / cities: Anchorage, Alaska • Hot Springs, Arkansas • Auburn, California + 331 more

Conditions: Heart Disease, Focus is on Testing Performance of CORA Hemostasis System.
Interventions: Not listed
Lead sponsor: Coramed Technologies LLC; Industry
Eligibility: 18 Years and older
Enrollment: 465 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Rochester, Minnesota + 1 more

Conditions: Colorectal Cancer
Interventions: irinotecan, fluorouracil, leucovorin calcium, oxaliplatin; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,691 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 430
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 261 more

Conditions: Acute Migraine
Interventions: Zavegepant (BHV-3500); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 974 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 67
States / cities: Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 62 more

Conditions: Ischemic Attack, Transient
Interventions: Clopidogrel, placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 4,881 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 147
States / cities: Chandler, Arizona • Tucson, Arizona • Carmichael, California + 95 more

Conditions: Constipation
Interventions: Squatting Assist Device, Sham Squatting Assist Device; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Respiratory Syncytial Virus, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure
Interventions: Not listed
Lead sponsor: MedImmune LLC; Industry
Eligibility: 50 Years and older
Enrollment: 476 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 21
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Denver, Colorado + 18 more

Search by objective public record fields.

Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF

Initial Case Series With Exalt Single-Use Duodenoscope - Expanded User Experience

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248

Bipolar Disorder Measures in Clinical Care

Familial Partial Lipodystrophy Study

A Study of PRN1008 in Patients With Pemphigus

Varenicline in Bipolar Depressed Patients

Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

PALbociclib CoLlaborative Adjuvant Study

TissueLink Versus SEAMGUARD After Distal Pancreatectomy

Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis

Abbott i-STAT High Sensitivity Troponin I Study

The LEADLESS II IDE Study for the Aveir VR Leadless Pacemaker System

Acceptance and Commitment Therapy for the Improvement of Cancer Distress in Patients With Incurable Cancers, ACT-C Trial

Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment

Equivalency Study of the TEG and CORA Hemostasis Systems

Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer

Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Use of a Squatting Assist Device in Patients With Constipation

An Observational Study to Assess RSV-associated Illness in Adults With COPD and/or CHF